0.629
price up icon27.59%   0.136
after-market 시간 외 거래: .58 -0.049 -7.79%
loading
전일 마감가:
$0.493
열려 있는:
$0.62
하루 거래량:
1.41M
Relative Volume:
12.00
시가총액:
$12.32M
수익:
-
순이익/손실:
$-26.56M
주가수익비율:
-0.9677
EPS:
-0.65
순현금흐름:
$-22.29M
1주 성능:
+20.91%
1개월 성능:
+0.75%
6개월 성능:
-35.01%
1년 성능:
-83.63%
1일 변동 폭
Value
$0.5501
$0.70
1주일 범위
Value
$0.477
$0.70
52주 변동 폭
Value
$0.477
$4.99

BiomX Inc Stock (PHGE) Company Profile

Name
명칭
BiomX Inc
Name
전화
972 7 23942377
Name
주소
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Name
직원
73
Name
트위터
@BiomX_Inc
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
PHGE's Discussions on Twitter

PHGE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PHGE
BiomX Inc
0.629 12.32M 0 -26.56M -22.29M -0.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

BiomX Inc Stock (PHGE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2021-04-15 개시 Ladenburg Thalmann Buy

BiomX Inc 주식(PHGE)의 최신 뉴스

pulisher
02:33 AM

HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World

02:33 AM
pulisher
Apr 01, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Critical Audit Alert: BiomX Receives Going Concern OpinionWhat This Means - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Phase 2 Trial Results - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Phage Therapy Market Know the Scope and Trends - openPR

Mar 27, 2025
pulisher
Mar 26, 2025

BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025
pulisher
Mar 20, 2025

BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 19, 2025
pulisher
Mar 09, 2025

BiomX’s $12 Million Financing - Global Legal Chronicle

Mar 09, 2025
pulisher
Mar 05, 2025

BiomX Inc. secures $12 million from recent offerings - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today

Mar 04, 2025
pulisher
Feb 27, 2025

BiomX Announces $12M Funding for BX004 Study - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

BiomX announces series of financings for aggregate gross proceeds of $12M - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan

Feb 26, 2025
pulisher
Feb 18, 2025

BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World

Feb 18, 2025
pulisher
Feb 06, 2025

Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve

Feb 06, 2025
pulisher
Jan 30, 2025

BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World

Jan 30, 2025
pulisher
Jan 26, 2025

Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World

Jan 26, 2025
pulisher
Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.

Jan 23, 2025
pulisher
Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire

Jan 23, 2025
pulisher
Jan 11, 2025

Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World

Jan 10, 2025
pulisher
Jan 07, 2025

BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World

Jan 07, 2025
pulisher
Dec 18, 2024

BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World

Dec 18, 2024
pulisher
Dec 16, 2024

BiomX regains NYSE compliance - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

BiomX Regains NYSE American Listing Compliance After Meeting All Standards - StockTitan

Dec 16, 2024
pulisher
Nov 21, 2024

BiomX (NYSEAMERICAN:PHGE) Stock Price Down 12.2% – Should You Sell? - Defense World

Nov 21, 2024
pulisher
Nov 20, 2024

BiomX (PHGE) 5-Day RSI : 13.43 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 16, 2024

BiomX Announces Third Quarter 2024 Financial Results and Clinical Program Updates - Defense World

Nov 16, 2024

BiomX Inc (PHGE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):